ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 180 filers reported holding ASCENDIS PHARMA A/S in Q1 2021. The put-call ratio across all filers is 1.02 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $118,404,971 | +22.0% | 1,264,470 | +16.3% | 0.04% | +28.1% |
Q2 2023 | $97,061,339 | -33.3% | 1,087,522 | -19.9% | 0.03% | -36.0% |
Q1 2023 | $145,559,084 | -11.3% | 1,357,574 | +1.0% | 0.05% | -12.3% |
Q4 2022 | $164,094,113 | +34.2% | 1,343,602 | +13.4% | 0.06% | +23.9% |
Q3 2022 | $122,296,000 | +57.5% | 1,184,356 | +41.8% | 0.05% | +70.4% |
Q2 2022 | $77,640,000 | -14.2% | 835,199 | +8.3% | 0.03% | 0.0% |
Q1 2022 | $90,477,000 | -10.6% | 770,929 | +2.5% | 0.03% | -3.6% |
Q4 2021 | $101,207,000 | -14.7% | 752,302 | +1.1% | 0.03% | -20.0% |
Q3 2021 | $118,584,000 | +28.7% | 743,979 | +6.2% | 0.04% | +29.6% |
Q2 2021 | $92,142,000 | +0.5% | 700,438 | -1.5% | 0.03% | -3.6% |
Q1 2021 | $91,639,000 | -21.4% | 711,045 | +1.7% | 0.03% | -24.3% |
Q4 2020 | $116,569,000 | +13.5% | 698,941 | +5.0% | 0.04% | 0.0% |
Q3 2020 | $102,740,000 | – | 665,757 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |